ANTENGENE-B(06996): IND for ATG-201 (CD19CD3 TCE) to treat autoimmune diseases approved in China.
Deqi Pharmaceuticals-B (06996) announced that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for the Phase I study of ATG-201, a CD19/CD3 bispecific T cell engager antibody for the treatment of B cell-mediated autoimmune diseases. Deqi Pharmaceuticals plans to quickly initiate and advance the Phase I study in China, while also preparing for clinical development of ATG-201 in Australia.
ANTENGENE-B (06996) announced that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for the Phase I study of ATG-201, a CD19/CD3 bispecific T cell engager antibody for the treatment of B cell-mediated autoimmune diseases. Deqi Pharmaceuticals plans to quickly initiate and advance the Phase I study in China, while also preparing for clinical development of ATG-201 in Australia.
Related Articles
Five major standard systems lead the reform. JD INDUSTRIALS (07618) is establishing a solid foundation for digitalization of the industrial supply chain through standardization.
Roadshow Record | China Green (02411): Store operations are steadily improving, with breakthroughs in multi-dimensional formats, and a clear path for long-term development.
HK Stock Market Move | ZJLD(06979) rises by over 6% again. Institutions point out that the company's actual operations are expected to be better than expected, with a net profit margin in the first half of the year reaching close to 20%.
Five major standard systems lead the reform. JD INDUSTRIALS (07618) is establishing a solid foundation for digitalization of the industrial supply chain through standardization.
Roadshow Record | China Green (02411): Store operations are steadily improving, with breakthroughs in multi-dimensional formats, and a clear path for long-term development.
HK Stock Market Move | ZJLD(06979) rises by over 6% again. Institutions point out that the company's actual operations are expected to be better than expected, with a net profit margin in the first half of the year reaching close to 20%.
